The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

[1]  Naijin Zhang,et al.  RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism , 2022, Cell Death Discovery.

[2]  B. Webb,et al.  Isocitrate dehydrogenase 3b is required for spermiogenesis but dispensable for retinal viability , 2022, The Journal of biological chemistry.

[3]  F. Yamasaki,et al.  The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas , 2022, Neuro-oncology.

[4]  C. Flask,et al.  Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors , 2022, Nature Cancer.

[5]  H. Colman,et al.  Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial , 2022, Neuro-oncology.

[6]  H. Döhner,et al.  Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. , 2022, The New England journal of medicine.

[7]  Wan Najbah Nik Nabil,et al.  Advances in therapeutic agents targeting quiescent cancer cells , 2022, Acta Materia Medica.

[8]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[9]  Lixia Chen,et al.  Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction. , 2021, Bioorganic chemistry.

[10]  S. Choe,et al.  Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation , 2021, JAMA oncology.

[11]  Hai Yan,et al.  The implications of IDH mutations for cancer development and therapy , 2021, Nature Reviews Clinical Oncology.

[12]  E. Maher,et al.  Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial , 2021, Clinical Cancer Research.

[13]  S. Heiland,et al.  Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas , 2021, Nature Cancer.

[14]  Hai Hu,et al.  The Roles of 2-Hydroxyglutarate , 2021, Frontiers in Cell and Developmental Biology.

[15]  H. Dombret,et al.  Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. , 2021, Blood.

[16]  D. Schiff,et al.  Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors , 2021, Clinical Cancer Research.

[17]  Lixia Chen,et al.  Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. , 2021, Journal of medicinal chemistry.

[18]  Xiang Huang,et al.  Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan‐cancer analysis , 2020, Molecular genetics & genomic medicine.

[19]  C. Kleer,et al.  Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity in Mice. , 2020, The Journal of clinical investigation.

[20]  T. Mak,et al.  IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis. , 2020, Blood.

[21]  Yuping Tang,et al.  Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening , 2020, Frontiers in Pharmacology.

[22]  S. Rocchi,et al.  Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy , 2020, Cell Death & Disease.

[23]  Z. Gong,et al.  Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression , 2020, Signal Transduction and Targeted Therapy.

[24]  Shou-ping Gong,et al.  LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma. , 2020, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[25]  O. Pedersen,et al.  Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.

[26]  H. Jeong,et al.  Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1) , 2020, AntiCancer Research.

[27]  Kyung-Sub Moon,et al.  Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma , 2020, Frontiers in Oncology.

[28]  Bingyan Wu,et al.  Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results , 2020, Leukemia.

[29]  G. Fuller,et al.  Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration , 2020, JCI insight.

[30]  The IDH1 Inhibitor Ivosidenib May Slow IDH1-Mutant Glioma Progression. , 2020, Cancer discovery.

[31]  M. Li,et al.  Wild-type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells , 2020, Molecular medicine reports.

[32]  Raymond Y Huang,et al.  Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Zhu,et al.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[34]  S. Choe,et al.  Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. , 2020, Blood advances.

[35]  Sarah E. Dorff,et al.  Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis , 2020, Clinical Cancer Research.

[36]  M. Heuser,et al.  Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia , 2020, Annals of Hematology.

[37]  M. Gilbert,et al.  IDH mutation in glioma: molecular mechanisms and potential therapeutic targets , 2020, British Journal of Cancer.

[38]  R. Geffers,et al.  Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia , 2020, Haematologica.

[39]  S. Choe,et al.  Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Collins,et al.  Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. , 2020, The Lancet. Haematology.

[41]  Chenqi Xu,et al.  Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities , 2020, Nature Metabolism.

[42]  R. Deberardinis,et al.  We need to talk about the Warburg effect , 2020, Nature Metabolism.

[43]  Mark T. Kershaw,et al.  Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. , 2020, Journal of medicinal chemistry.

[44]  I. Mellinghoff,et al.  Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma , 2020, ACS medicinal chemistry letters.

[45]  Sun Li,et al.  I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  C. Luo,et al.  Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor. , 2019, Bioorganic & medicinal chemistry letters.

[47]  E. Shang,et al.  Novel IDH1-Targeted Glioma Therapies. , 2019, CNS drugs.

[48]  Jennie W. Taylor,et al.  ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS , 2019, Neuro-Oncology.

[49]  T. Soga,et al.  Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma , 2019, Oncogene.

[50]  N. Zhang,et al.  PAX5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy , 2019, Cell Death & Disease.

[51]  C. Luo,et al.  Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening. , 2019, Bioorganic & medicinal chemistry.

[52]  M. Heuser,et al.  In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site , 2019, Leukemia.

[53]  Mark T. Kershaw,et al.  Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. , 2019, Journal of medicinal chemistry.

[54]  M. Pereira,et al.  Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going? , 2019, Current drug targets.

[55]  K. Cassady,et al.  TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair , 2019, Front. Oncol..

[56]  J. Lozano-Sánchez,et al.  An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors , 2018, Carcinogenesis.

[57]  Min Huang,et al.  Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. , 2018, Bioorganic & Medicinal Chemistry Letters.

[58]  A. Viale,et al.  Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. , 2018, Cancer discovery.

[59]  Yanjun Wang,et al.  IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 , 2018, Royal Society Open Biology.

[60]  P. Singh,et al.  RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer , 2018, Molecular Cancer Research.

[61]  C. Yun,et al.  Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. , 2018, Biochemical and biophysical research communications.

[62]  Lixia Chen,et al.  Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1. , 2018, Bioorganic chemistry.

[63]  Jian-rong Gao,et al.  3‐(7‐Azaindolyl)‐4‐indolylmaleimides as a novel class of mutant isocitrate dehydrogenase‐1 inhibitors: Design, synthesis, and biological evaluation , 2018, Archiv der Pharmazie.

[64]  G. Reifenberger,et al.  D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells , 2018, Clinical Cancer Research.

[65]  B. Firestone,et al.  Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. , 2018, ACS medicinal chemistry letters.

[66]  M. Weller,et al.  Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate , 2018, Nature Medicine.

[67]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[68]  Diana Yu,et al.  Mutant IDH1 Promotes Glioma Formation In Vivo , 2018, Cell reports.

[69]  Lea Kristin Röver,et al.  PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations , 2018, EBioMedicine.

[70]  S. Gross,et al.  Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers , 2018, ACS medicinal chemistry letters.

[71]  A. von Deimling,et al.  Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. , 2017, Bioorganic & medicinal chemistry letters.

[72]  A. von Deimling,et al.  Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. , 2017, Bioorganic & medicinal chemistry.

[73]  Min Huang,et al.  Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[74]  B. Firestone,et al.  Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. , 2017, ACS medicinal chemistry letters.

[75]  Christian M. Metallo,et al.  Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. , 2017, Cancer research.

[76]  S. Su,et al.  Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. , 2017, Annual review of biochemistry.

[77]  Jiahuai Han,et al.  2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. , 2017, Cell reports.

[78]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[79]  G. J. Khan,et al.  IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[80]  Weiguang Sun,et al.  Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1 , 2017, Oncotarget.

[81]  Lianzhong Luo,et al.  IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation. , 2017, Cell reports.

[82]  J. Costello,et al.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.

[83]  L. Yao,et al.  Chronic inflammation confers to the metabolic reprogramming associated with tumorigenesis of colorectal cancer , 2017, Cancer biology & therapy.

[84]  C. Burant,et al.  Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. , 2017, Cancer research.

[85]  Amar Deep Sharma,et al.  Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo , 2017, Leukemia.

[86]  A. Unterberg,et al.  Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo , 2017, Acta Neuropathologica.

[87]  Michael D. Jones,et al.  Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. , 2017, ACS medicinal chemistry letters.

[88]  C. James,et al.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. , 2015, Cell reports.

[89]  M. Wigglesworth,et al.  Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells. , 2016, Journal of medicinal chemistry.

[90]  P. Wen,et al.  A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations , 2016 .

[91]  H. Ishii,et al.  Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer , 2016, Scientific Reports.

[92]  S. de Botton,et al.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives , 2016, Journal of blood medicine.

[93]  S. Schreiber,et al.  Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. , 2016, ACS medicinal chemistry letters.

[94]  W. Stec,et al.  IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis , 2016, PloS one.

[95]  J. Engh,et al.  IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. , 2016, Neuro-oncology.

[96]  Yi Jin,et al.  R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling. , 2016, The international journal of biochemistry & cell biology.

[97]  Y. Keum,et al.  Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1. , 2015, Bioorganic & medicinal chemistry letters.

[98]  Shimin Zhao,et al.  NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. , 2015, Molecular cell.

[99]  Nicholas D. Adams,et al.  New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. , 2015, Nature chemical biology.

[100]  A. Iwama,et al.  [Mutations of epigenetic regulator genes and myeloid malignancies]. , 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[101]  J. W. Allwood,et al.  Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells , 2015, Scientific Reports.

[102]  A. Klein-Szanto,et al.  Regulation of HIF‐1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells , 2015, Molecular carcinogenesis.

[103]  Xiang Wang,et al.  IDH1, a CHOP and C/EBPβ-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis. , 2015, Cancer letters.

[104]  T. Graeber,et al.  2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. , 2015, Cell metabolism.

[105]  B. Zheng,et al.  Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. , 2015, Journal of medicinal chemistry.

[106]  S. Inoue,et al.  Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+/NADPH ratio , 2015, Cell Death and Differentiation.

[107]  John D. Heiss,et al.  New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma , 2015, International journal of medical sciences.

[108]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[109]  Huafeng Zhang,et al.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression , 2015, Cellular and Molecular Life Sciences.

[110]  D. Fan,et al.  Loss of vinculin and membrane-bound β-catenin promotes metastasis and predicts poor prognosis in colorectal cancer , 2014, Molecular Cancer.

[111]  Tomas Radivoyevitch,et al.  The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. , 2014, Biochimica et biophysica acta.

[112]  Dietmar Hoffmann,et al.  Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule , 2014, The Journal of Biological Chemistry.

[113]  B. Zheng,et al.  Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity , 2014, Journal of medicinal chemistry.

[114]  V. Rangnekar,et al.  The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells , 2014, Acta Neuropathologica.

[115]  Ju-bo Wang,et al.  Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells , 2014, Oncology letters.

[116]  Ju-bo Wang,et al.  IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[117]  F. Pontén,et al.  WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism , 2013, Carcinogenesis.

[118]  Jinlong Shi,et al.  An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation , 2014, Neurological Sciences.

[119]  Janna H. Neltner,et al.  Autophagy and oxidative stress in gliomas with IDH1 mutations , 2014, Acta Neuropathologica.

[120]  Feng Liu,et al.  mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. , 2013, Cell metabolism.

[121]  Sung Soo Kim,et al.  Cancer cell metabolism: implications for therapeutic targets , 2013, Experimental & Molecular Medicine.

[122]  W. Yung,et al.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.

[123]  B. Prasad,et al.  Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. , 2013, ACS medicinal chemistry letters.

[124]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[125]  W. Kaelin,et al.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.

[126]  Xun Zhu,et al.  MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. , 2013, The Journal of clinical investigation.

[127]  M. Mimeault,et al.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells , 2013, Journal of cellular and molecular medicine.

[128]  Chandra Verma,et al.  Functional relevance of dynamic properties of Dimeric NADP-dependent Isocitrate Dehydrogenases , 2012, BMC Bioinformatics.

[129]  J. Vadgama,et al.  Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells , 2012, Molecular Cancer Research.

[130]  Jesse S. Voss,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.

[131]  S. Gross,et al.  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. , 2012, ACS medicinal chemistry letters.

[132]  R. Yantiss,et al.  Metabolic Profiling, a Noninvasive Approach for the Detection of Experimental Colorectal Neoplasia , 2012, Cancer Prevention Research.

[133]  Konrad Basler,et al.  The many faces and functions of β‐catenin , 2012, The EMBO journal.

[134]  Fabian V. Filipp,et al.  Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells , 2012, Pigment cell & melanoma research.

[135]  Kristian Helin,et al.  Molecular mechanisms and potential functions of histone demethylases , 2012, Nature Reviews Molecular Cell Biology.

[136]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[137]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[138]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[139]  Ji Young Kim,et al.  Expression of cytosolic NADP(+)-dependent isocitrate dehydrogenase in melanocytes and its role as an antioxidant. , 2012, Journal of dermatological science.

[140]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[141]  Verena I Gaidzik,et al.  TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  S. Dikalov.  Cross talk between mitochondria and NADPH oxidases. , 2011, Free radical biology & medicine.

[143]  P. Birner,et al.  Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. , 2011, Folia neuropathologica.

[144]  R. Irby,et al.  The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model , 2011, Clinical Cancer Research.

[145]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[146]  K. Gardner,et al.  Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B , 2011, Proceedings of the National Academy of Sciences.

[147]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[148]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[149]  Kristian Helin,et al.  Histone demethylases in development and disease. , 2010, Trends in cell biology.

[150]  P. Dorrestein,et al.  PHF8 Mediates Histone H4 Lysine 20 Demethylation Events Involved in Cell Cycle Progression , 2010, Nature.

[151]  Hai Yan,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.

[152]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[153]  A. Azmi,et al.  PAR-4 as a possible new target for pancreatic cancer therapy , 2010, Expert opinion on therapeutic targets.

[154]  Jun Luo,et al.  The expression and significance of IDH1 and p53 in osteosarcoma , 2010, Journal of experimental & clinical cancer research : CR.

[155]  M. Saegusa,et al.  Transcriptional regulation of pro‐apoptotic Par‐4 by NF‐κB/p65 and its function in controlling cell kinetics during early events in endometrial tumourigenesis , 2010, The Journal of pathology.

[156]  Jun O. Liu,et al.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. , 2010, Cancer cell.

[157]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[158]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[159]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[160]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[161]  V. Rangnekar,et al.  The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis , 2009, Cell.

[162]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[163]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[164]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[165]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[166]  M.-H. Lee,et al.  Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.

[167]  Min Gyu Lee,et al.  Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.

[168]  G. Semenza,et al.  HIF-1 mediates the Warburg effect in clear cell renal carcinoma , 2007, Journal of bioenergetics and biomembranes.

[169]  A. Rao,et al.  The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation , 2007, Nature.

[170]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[171]  M. Jensen,et al.  A Pyruvate Cycling Pathway Involving Cytosolic NADP-dependent Isocitrate Dehydrogenase Regulates Glucose-stimulated Insulin Secretion* , 2006, Journal of Biological Chemistry.

[172]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[173]  Yi Zhang,et al.  JmjC-domain-containing proteins and histone demethylation , 2006, Nature Reviews Genetics.

[174]  Karl Mechtler,et al.  Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. , 2006, Genes & development.

[175]  H. Erdjument-Bromage,et al.  Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.

[176]  T. Huh,et al.  Cytosolic NADP+-dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism* , 2004, Journal of Biological Chemistry.

[177]  Jianping Ding,et al.  Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.

[178]  Young Sang Kim,et al.  Cytosolic NADP(+)-dependent isocitrate dehydrogenase protects macrophages from LPS-induced nitric oxide and reactive oxygen species. , 2004, Biochemical and biophysical research communications.

[179]  J. Lambeth.  NOX enzymes and the biology of reactive oxygen , 2004, Nature Reviews Immunology.

[180]  T. Huh,et al.  Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. , 2002, Free radical biology & medicine.

[181]  E. Selker,et al.  A histone H3 methyltransferase controls DNA methylation in Neurospora crassa , 2001, Nature.

[182]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[183]  I-Hsien Wu,et al.  Stress-induced binding of the transcriptional factor CHOP to a novel DNA control element , 1996, Molecular and cellular biology.

[184]  D. Ron,et al.  CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. , 1992, Genes & development.